Testing of cryopreserved concentrates at infusion leads to standardization of engraftment in autologous peripheral blood progenitor cell transplantation
Abstract
The aim of the study performed at 29 patients undergoing autologous peripheral blood progenitor cell (PBPC) transplantation was to obtain data on total number of thawed infused nucleated cells and on their viability as well as on the number of infused CD34+ cells and CFU-GM. To prevent delayed engraftment (more than 21 days) the minimum cell dose per kg of patient's weight was adjusted to 2x10exp6 CD34+ and 2x10exp5 CFU-GM.
As the PBPC concentrates were cryopreserved in presence of 10% dimethylsulphoxide (DMSO) the consequences of this approach on the total infused volume were evaluated. Engraftment within 21 days was achieved in 97 % of patients.
The effort to control the risk of delayed engraftment led, however, to the need to accept higher risk of DMSO toxicity.